



N Burchardi

Kontakt

N Burchardi

Publikationen (6)

Loibl S, Schmitt W, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P, Weber K, Rhiem K, Denkert C, Jackisch C, Rezaei M, Engels K, Untch M, Burchardi N, Huober J, Sinn B, Blohmer J, Grischke E, Furlanetto J, Tesch H, Hanusch C, Schneeweiss A. Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]. *Ann Oncol* 2022; 33:743-744.

Fasching P, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler R, Hahnen E, Untch M, Burchardi N, Blohmer J, Loibl S, Doering G, Uleer C, Schmitt W, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober J, Stefek A, Seiler S, German Breast Group and Arbeitsgemeinschaft Gynäkologische Onkologie Breast. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). *Ann Oncol* 2020; 32:49-57.

Loibl S, Schmitt W, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching P, Weber K, Rhiem K, Denkert C, Jackisch C, Rezaei M, Engels K, Untch M, Burchardi N, Huober J, Sinn B, Blohmer J, Grischke E, Furlanetto J, Tesch H, Hanusch C, Schneeweiss A. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. *Ann Oncol* 2019; 30:1279-1288.

von Minckwitz G, Jackisch C, Kümmel S, Fasching P, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S, Hanusch C, Denkert C, Rezaei M, Tesch H, Huober J, Gerber B, Zahm D, Hilfrich J, Costa S, Dubsy P, Blohmer J, German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29). *Eur J Cancer* 2016; 64:12-21.

Baumann K, Lück H, Vergote I, Schmalfeldt B, Huober J, Sehouli J, Loibl S, du Bois A, Kurzeder C, Burchardi N, Wimberger P, Pfisterer J, Wagner U. Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. *Gynecol Oncol* 2011; 123:27-32.

du Bois A, Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe Ovarialkarzinom, Kölbl H, Jackisch C, Stähle A, Burges A, Wimberger P, Huober J, Loibl S, Burchardi N, Pfisterer J, Kommission Uterus. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). *Gynecologic oncology* 2007; 107:518-25.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch